This clinical trial is focused on studying the effects of different inhalation treatments for people with Chronic Obstructive Pulmonary Disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. The study will compare the effects of a combination of medications delivered through a metered dose inhaler (MDI). These medications include Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate Dihydrate, referred to as BGF MDI. Another combination being studied is Budesonide and Formoterol Fumarate, known as BFF MDI. A placebo MDI, which looks like the real medication but does not contain active ingredients, will also be used for comparison.

The purpose of the study is to assess how these treatments affect breathing and exercise capacity in people with COPD. Participants will use each of the inhalers, including the placebo, during different periods of the study. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know which treatment is being used at any given time, to ensure unbiased results. The study will take place over several weeks, with participants visiting the study site for assessments and to receive their inhalers.

Throughout the study, participants will be monitored for changes in their breathing and exercise performance. The main focus will be on how well the lungs can expand during exercise, known as “dynamic hyperinflation.” This will help researchers understand the effectiveness of the BGF MDI compared to the BFF MDI and the placebo. Participants will also be observed for any side effects or adverse reactions to the treatments. The study aims to provide valuable information on how these inhalation treatments can help manage COPD symptoms and improve quality of life for those affected by the disease.